[go: up one dir, main page]

HRP20192197T2 - CARBAZOLE DERIVATIVES - Google Patents

CARBAZOLE DERIVATIVES Download PDF

Info

Publication number
HRP20192197T2
HRP20192197T2 HRP20192197TT HRP20192197T HRP20192197T2 HR P20192197 T2 HRP20192197 T2 HR P20192197T2 HR P20192197T T HRP20192197T T HR P20192197TT HR P20192197 T HRP20192197 T HR P20192197T HR P20192197 T2 HRP20192197 T2 HR P20192197T2
Authority
HR
Croatia
Prior art keywords
carbazole
carboxamide
fluoro
tetrahydro
hydroxypropan
Prior art date
Application number
HRP20192197TT
Other languages
Croatian (hr)
Inventor
Saleem Ahmad
Douglas G Batt
Qingjie Liu
John E. Macor
Joseph A. Tino
Scott Hunter Watterson
Satheesh Kesavan NAIR
Tarun Kumar MAISHAL
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20192197(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20192197T1 publication Critical patent/HRP20192197T1/en
Publication of HRP20192197T8 publication Critical patent/HRP20192197T8/en
Publication of HRP20192197T2 publication Critical patent/HRP20192197T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Claims (18)

1. Spoj formule (I) [image] ili njegova sol, gdje: dvije isprekidane linije predstavljaju ili dvije jednostruke ili dvije dvostruke veze; i R1b i R2b su prisutni samo ako su dvije isprekidane linije dvije jednostruke veze; Q je: (i) [image] (ii) [image] [image] (iii) [image] [image] [image] ili (iv) [image] [image] [image] R1a je: (i) H, -CN, -CF3, -CH3, -CR8aR8bOH, -CR8aR8bCR8aR8bOH, -CH(OH)CH2OH, -NHR9, -C(O)NR10aR10b, -C(O)(morfolinil), -C(O)(piperazinil), ili -C(O)(metil piperazinil); ili (ii) [image] R1b, kada je prisutan, je H ili -CH3, pod uvjetom da ako R1a je H onda R1b je također H; R2a je H, F, ili Cl, pod uvjetom da ako R1a je drugačije od H onda R2a je H; R2b, kada je prisutan, je isti kao R2a; R3 je H, F, ili Cl; R4 je H, F, Cl, ili -CH3; R5a je H, F, Cl, -OCH3, ili -OCF3; R5b je H, F, Cl, -OCH3, ili -OCF3; R6a je H, -CH3 ili ciklopropil; R6c je H, -CH3 ili ciklopropil; R7a je -C(O)CH=CH(R11), -C(O)C≡CR12, ili -S(O)2CH=CH2; R7b je -C(O)CH=CH2; R7c je -C(O)CH=CH2 ili -C(O)C≡CR12; R7d je -CN, -C(O)CH=CH2, ili -C(O)C≡CR13; R7e je -CH=CH2 ili -C≡CR13; R7f je pirolidinil supstituiran sa R7c, -CH=CHC(O)(morfolinil), ili -CH=CHC(O)(pirolidinil); R8a je H ili -CH3; R8b je H ili -CH3; R9 je C1-4 alkil; R10a i R10b su nezavisno H ili -CH3; R11 je H ili -CH3; R12 je H, C1-4 alkil, ili ciklopropil; i R13 je H, C1-4 alkil, ili ciklopropil; pod uvjetima da: (a) ako Q je [image] i R7d je -CN ili -C(O)CH=CH2, onda R3 je H; i (b) ako isprekidane linije predstavljaju dvije jednostruke veze, onda: (i) Q nije [image] (ii) R11, ako je prisutan, je H; i (iii) spoj formule (I) nije: [image] 1. Compound of formula (I) [image] or its salt, where: two dashed lines represent either two single or two double bonds; both R1b and R2b are present only if the two dashed lines are two single bonds; Q is: (and) [image] (ii) [image] [image] (iii) [image] [image] [image] or (iv) [image] [image] [image] R1a is: (i) H, -CN, -CF3, -CH3, -CR8aR8bOH, -CR8aR8bCR8aR8bOH, -CH(OH)CH2OH, -NHR9, -C(O)NR10aR10b, -C(O)(morpholinyl), -C(O )(piperazinyl), or -C(O)(methyl piperazinyl); or (ii) [image] R 1b , when present, is H or -CH 3 , provided that if R 1a is H then R 1b is also H; R 2a is H, F, or Cl, provided that if R 1a is other than H then R 2a is H; R2b, when present, is the same as R2a; R 3 is H, F, or Cl; R 4 is H, F, Cl, or -CH 3 ; R5a is H, F, Cl, -OCH3, or -OCF3; R5b is H, F, Cl, -OCH3, or -OCF3; R6a is H, -CH3 or cyclopropyl; R6c is H, -CH3 or cyclopropyl; R7a is -C(O)CH=CH(R11), -C(O)C≡CR12, or -S(O)2CH=CH2; R7b is -C(O)CH=CH2; R7c is -C(O)CH=CH2 or -C(O)C≡CR12; R7d is -CN, -C(O)CH=CH2, or -C(O)C≡CR13; R7e is -CH=CH2 or -C≡CR13; R7f is pyrrolidinyl substituted with R7c, -CH=CHC(O)(morpholinyl), or -CH=CHC(O)(pyrrolidinyl); R 8a is H or -CH 3 ; R8b is H or -CH3; R 9 is C 1-4 alkyl; R10a and R10b are independently H or -CH3; R 11 is H or -CH 3 ; R 12 is H, C 1-4 alkyl, or cyclopropyl; and R 13 is H, C 1-4 alkyl, or cyclopropyl; under the conditions that: (a) if Q is [image] and R7d is -CN or -C(O)CH=CH2, then R3 is H; and (b) if the dashed lines represent two single bonds, then: (i) Q is not [image] (ii) R 11 , if present, is H; and (iii) the compound of formula (I) is not: [image] 2. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, gdje: Q je [image] [image] [image] R1a je: (i) H, -CN, -CF3, -CH3, -CR8aR8bOH, -CH(OH)CH2OH, -NHR9, ili -C(O)NR10aR10b; ili (ii) [image] R1b, kada je prisutan, je H ili -CH3, pod uvjetom da ako R1a je H onda R1b je također H; R2a je H ili F, pod uvjetom da ako R1a je drugačije od H onda R2a je H; R2b, kada je prisutan, je isti kao R2a; R3 je H, F, ili Cl; R4 je H, F, Cl, ili -CH3; R5a je H, F, Cl, -OCH3, ili -OCF3; R5b je H, F, Cl, -OCH3, ili -OCF3; R6a je H, -CH3 ili ciklopropil; R6c je H, -CH3 ili ciklopropil; R7a je -C(O)CH=CH(R11), -C(O)C≡CR12, ili -S(O)2CH=CH2; R7b je -C(O)CH=CH2; R7c je -C(O)CH=CH2 ili -C(O)C≡CR12; R7d je -C(O)CH=CH2 ili -C(O)C≡CR13; R8a je H ili -CH3; R8b je H ili -CH3; R9 je C1-4 alkil; R10a i R10b su nezavisno H ili -CH3; R11 je H ili -CH3; R12 je H, C1-4 alkil, ili ciklopropil; i R13 je H, C1-4 alkil, ili ciklopropil; pod uvjetom da ako isprekidane linije predstavljaju dvije jednostruke veze, onda: (i) Q nije [image] (ii) R11, ako je prisutan, je H; i (iii) spoj formule (I) nije: [image] 2. The compound according to claim 1 or its salt, where: Q is [image] [image] [image] R1a is: (i) H, -CN, -CF3, -CH3, -CR8aR8bOH, -CH(OH)CH2OH, -NHR9, or -C(O)NR10aR10b; or (ii) [image] R 1b , when present, is H or -CH 3 , provided that if R 1a is H then R 1b is also H; R 2a is H or F, provided that if R 1a is other than H then R 2a is H; R2b, when present, is the same as R2a; R 3 is H, F, or Cl; R 4 is H, F, Cl, or -CH 3 ; R5a is H, F, Cl, -OCH3, or -OCF3; R5b is H, F, Cl, -OCH3, or -OCF3; R6a is H, -CH3 or cyclopropyl; R6c is H, -CH3 or cyclopropyl; R7a is -C(O)CH=CH(R11), -C(O)C≡CR12, or -S(O)2CH=CH2; R7b is -C(O)CH=CH2; R7c is -C(O)CH=CH2 or -C(O)C≡CR12; R7d is -C(O)CH=CH2 or -C(O)C≡CR13; R 8a is H or -CH 3 ; R8b is H or -CH3; R 9 is C 1-4 alkyl; R10a and R10b are independently H or -CH3; R 11 is H or -CH 3 ; R 12 is H, C 1-4 alkyl, or cyclopropyl; and R 13 is H, C 1-4 alkyl, or cyclopropyl; provided that if the dashed lines represent two single bonds, then: (i) Q is not [image] (ii) R 11 , if present, is H; and (iii) the compound of formula (I) is not: [image] 3. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, gdje: R1a je H, -CN, -CF3, -CH3, -CR8aR8bOH, -CH(OH)CH2OH, -NHR9, ili -C(O)NR10aR10b.3. The compound according to claim 1 or its salt, where: R1a is H, -CN, -CF3, -CH3, -CR8aR8bOH, -CH(OH)CH2OH, -NHR9, or -C(O)NR10aR10b. 4. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, gdje: R6a je H ili -CH3; R6c je H ili -CH3; R7a je -C(O)CH=CH(R11) ili -S(O)2CH=CH2; i R13 je H.4. The compound according to claim 1 or its salt, where: R6a is H or -CH3; R6c is H or -CH3; R7a is -C(O)CH=CH(R11) or -S(O)2CH=CH2; and R13 is H. 5. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, koje ima strukturu formule (Ia): [image] 5. A compound according to claim 1 or a salt thereof, which has the structure of formula (Ia): [image] 6. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, koje ima strukturu formule (Ib): [image] 6. A compound according to claim 1 or its salt, which has the structure of formula (Ib): [image] 7. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, gdje: Q je [image] 7. The compound according to claim 1 or its salt, where: Q is [image] 8. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, gdje: Q je [image] 8. A compound according to claim 1 or its salt, where: Q is [image] 9. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, gdje R1a je H, -CN, -CF3, -CH3, -CR8aR8bOH, -CR8aR8bCR8aR8bOH, -CH(OH)CH2OH, -NHR9, -C(O)NR10aR10b, -C(O)(morfolinil), -C(O)(piperazinil), ili -C(O)(metil piperazinil)9. A compound according to claim 1 or a salt thereof, where R1a is H, -CN, -CF3, -CH3, -CR8aR8bOH, -CR8aR8bCR8aR8bOH, -CH(OH)CH2OH, -NHR9, -C(O)NR10aR10b, -C(O)(morpholinyl), -C(O)(piperazinyl), or -C(O)(methyl piperazinyl) 10. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, gdje R3 je F ili Cl.10. A compound according to claim 1 or a salt thereof, where R3 is F or Cl. 11. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, gdje R3 je F.11. A compound according to claim 1 or a salt thereof, wherein R3 is F. 12. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, gdje je navedeno spoj: (RS)-5-(3-akrilamidofenil)-2-(2-hidroksipropan-2-il)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (1); (RS)-2-(2-hidroksipropan-2-il)-5-(2-metil-3-(N-metilvinilsulfonamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (2); 5-(3-akrilamido-2-metilfenil)-2,2-dimetil-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (3); 4-(3-akrilamido-2-metilfenil)-7-(2-hidroksipropan-2-il)-9H-karbazol-1-karboksamid (4); (RS)-2-(2-hidroksipropan-2-il)-5-(3-(vinilsulfonamido) fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (5); (RS)-4-(3-akrilamido-2-metilfenil)-3-kloro-7-(2-hidroksipropan-2-il)-9H-karbazol-1-karboksamid (6); 5-(3-akrilamido-2-metilfenil)-2-(hidroksimetil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (7); (RS)-5-(3-akrilamido-2-metilfenil)-6-kloro-2-(hidroksimetil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid, smjesa dijastereomera (8); 5-(3-akrilamido-2-metilfenil)-6-kloro-2,3,4,9-tetrahidro-1H-karbazol-2,8-dikarboksamid, smjesa dijastereomera (9); (RS)-5-(3-akrilamido-2-metilfenil)-2-(2-hidroksipropan-2-il)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (10); (RS)-(E)-4-(3-(but-2-enamido)-2-metilfenil)-3-kloro-7-(2-hidroksipropan-2-il)-9H-karbazol-1-karboksamid (11); 5-(3-akrilamido-2-metilfenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (12); (RS)-2-(2-hidroksipropan-2-il)-5-(2-metil-3-(vinilsulfonamido) fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (13); (RS)-5-(3-akrilamido-2-metilfenil)-2,3,4,9-tetrahidro-1H-karbazol-2,8-dikarboksamid (14); 4-(3-akrilamido-2-metilfenil)-7-cijano-9H-karbazol-1-karboksamid (15); (RS)-4-(3-akrilamido-2-metilfenil)-7-(1,2-dihidroksietil)-9H karbazol-1-karboksamid (16); 4-(3-akrilamido-2-metilfenil)-7-(izopropilamino)-9H-karbazol-1-karboksamid (17); (RS)-5-(3-akrilamido-2-metilfenil)-N2,N2-dimetil-2,3,4,9-tetrahidro-1H-karbazol-2,8-dikarboksamid (18); (RS)-2-(2-hidroksipropan-2-il)-5-(2-metil-3-(N-metilakrilamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (19); (RS)-2-(hidroksimetil)-5-(2-metil-3-(N-metilakrilamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (20); (RS)-N2,N2-dimetil-5-(2-metil-3-(N-metilakrilamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-2,8-dikarboksamid (21); (2R)-6-fluoro-2-(2-hidroksipropan-2-il)-5-(2-metil-3-(N-metilvinilsulfonamido) fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid, smjesa dijastereomera (22); (2R)-6-kloro-2-(2-hidroksipropan-2-il)-5-(2-metil-3-(N-metilvinilsulfonamido) fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid, smjesa dijastereomera (23); (2R)-6-fluoro-2-(2-hidroksipropan-2-il)-5-(3-(N-metilvinilsulfonamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid, jedan enantiomer (24); (2R)-6-kloro-2-(2-hidroksipropan-2-il)-5-(3-(N-metilvinilsulfonamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid, jedan enantiomer (25); (RS)-2-(2-hidroksipropan-2-il)-5-(3-(N-metilvinilsulfonamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (26); 7-(2-hidroksipropan-2-il)-4-(2-metil-3-(N-metilvinilsulfonamido)fenil)-9H-karbazol-1-karboksamid (27); 7-(2-hidroksipropan-2-il)-4-(3-(N-metilvinilsulfonamido)fenil)-9H-karbazol-1-karboksamid (28); (RS)-3-fluoro-7-(2-hidroksipropan-2-il)-4-(2-metil-3-(vinilsulfonamido)fenil)-9H-karbazol-1-karboksamid (29); (RS)-3-fluoro-7-(2-hidroksipropan-2-il)-4-(2-metil-3-(N-metilvinilsulfonamido)fenil)-9H-karbazol-1-karboksamid (30); 3-fluoro-7-(2-hidroksipropan-2-il)-4-(3-(N-metilvinilsulfonamido)fenil)-9H-karbazol-1-karboksamid (31); 7-(2-hidroksipropan-2-il)-4-(2-metil-3-(vinilsulfonamido)fenil)-9H-karbazol-1-karboksamid (32); 7-(2-hidroksipropan-2-il)-4-(3-(vinilsulfonamido) fenil)-9H-karbazol-1-karboksamid (33); 3-fluoro-7-(2-hidroksipropan-2-il)-4-(3-(vinilsulfonamido)fenil)-9H-karbazol-1-karboksamid (34); (RS)-2-(2-hidroksipropan-2-il)-5-(3-(N-metilakrilamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (35); (R)-6-fluoro-2-(2-hidroksipropan-2-il)-5-(3-(N-metilakrilamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (36); 7-(2-hidroksipropan-2-il)-4-(3-(N-metilakrilamido)fenil)-9H-karbazol-1-karboksamid (37); 3-fluoro-7-(2-hidroksipropan-2-il)-4-(3-(N-metilakrilamido)fenil)-9H-karbazol-1-karboksamid (38); (R)-6-kloro-2-(2-hidroksipropan-2-il)-5-(3-(N-metilakrilamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (39); (S)-2-(2-hidroksipropan-2-il)-5-(3-(vinilsulfonamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (40); (R)-2-(2-hidroksipropan-2-il)-5-(3-(vinilsulfonamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (41); (RS)-5-(2-fluoro-3-(N-metilakrilamido)fenil)-2-(2-hidroksipropan-2-il)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (42); (R)-6-fluoro-2-(2-hidroksipropan-2-il)-5-(3-(vinilsulfonamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (43); (2R)-6-kloro-2-(2-hidroksipropan-2-il)-5-(2-metil-3-(vinilsulfonamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid, smjesa dijastereomera (44); (RS)-5-(2-fluoro-3-(N-metilvinilsulfonamido)fenil)-2-(2-hidroksipropan-2-il)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (45); (RS)-5-(2-kloro-3-(N-metilvinilsulfonamido)fenil)-2-(2-hidroksipropan-2-il)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (46); (2R)-6-fluoro-2-(2-hidroksipropan-2-il)-5-(2-metil-3-(vinilsulfonamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid, smjesa dijastereomera (47); 5-(3-(vinilsulfonamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (48); 5-(2-metil-3-(vinilsulfonamido)fenil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (49); (RS)-5-(3-akrilamido-4-metoksifenil)-2-(2-hidroksipropan-2-il)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (50); (RS)-5-(3-akrilamido-4-(trifluorometoksi)fenil)-2-(2-hidroksipropan-2-il)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (51); (RS)-5-(3-akrilamido-4-fluorofenil)-2-(2-hidroksipropan-2-il)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (52); (RS)-5-(3-akrilamido-2-metilfenil)-2-metil-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (53); (RS)-5-(3-akrilamido-2-metilfenil)-2-(trifluorometil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (54); 5-(3-akrilamido-2-metilfenil)-6-kloro-2-(hidroksimetil)-2-metil-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid, pojedinačni racemični dijastereomeri (55 i 56); 5-(3-akrilamido-2-metilfenil)-6-kloro-N2,N2-dimetil-2,3,4,9-tetrahidro-1H-karbazol-2,8-dikarboksamid, pojedinačni racemični dijastereomeri (57 i 58); 5-(3-akrilamido-2-metilfenil)-6-kloro-2-(2-hidroksipropan-2-il)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid, pojedinačni racemični dijastereomeri (59 i 60); 5-(3-akrilamido-2-metilfenil)-6-kloro-2-(2-hidroksipropan-2-il)-2-metil-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid, pojedinačni racemični dijastereomeri (61 i 62); (S)-5-((1-akriloilpirolidin-3-il)amino)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (63); (E)-4-(3-(but-2-enamido)-2-metilfenil)-7-(2-hidroksipropan-2-il)-9H-karbazol-1-karboksamid (64); 5-(((S)-1-akriloilpirolidin-3-il)amino)-2-(trifluorometil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid, smjesa dijastereomera (65); (S)-5-(3-akrilamidopiperidin-1-il)-3,3,6-trifluoro-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (66); (S)-4-(3-akrilamidopiperidin-1-il)-3-fluoro-9H-karbazol-1-karboksamid (69); 5-(((S)-1-propioloilpirolidin-3-il)amino)-2-(RS)-(trifluorometil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid, smjesa dijastereomera (72); (S)-5-(3-(but-2-inamido) piperidin-1-il)-3,3,6-trifluoro-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (73); (S)-3-fluoro-4-(3-(N-metilbut-2-inamido)piperidin-1-il)-9H-karbazol-1-karboksamid (74); (S)-4-(3-(but-2-inamido)piperidin-1-il)-3-fluoro-9H-karbazol-1-karboksamid (75); (S)-4-(3-(3-ciklopropilpropiolamido)piperidin-1-il)-3-fluoro-9H-karbazol-1-karboksamid (76); 5-(((S)-1-akriloilpirolidin-3-il)amino)-2-(trifluorometil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid, pojedinačni dijastereomeri (77 i 78); 3-fluoro-4-((6-vinilpiridin-3-il)metil)-9H-karbazol-1-karboksamid (87); (RS)-4-(2-akriloilisoindolin-4-il)-3-fluoro-9H-karbazol-1-karboksamid (89); 4-(2-akriloil-1,2,3,4-tetrahidroizohinolin-7-il)-3-fluoro-9H-karbazol-1-karboksamid (90); 4-(2-akriloil-1,2,3,4-tetrahidroizohinolin-6-il)-3-fluoro-9H-karbazol-1-karboksamid (91); 4-(1-akriloilindolin-4-il)-3-fluoro-9H-karbazol-1-karboksamid (92); 4-(1-akriloilindolin-6-il)-3-fluoro-9H-karbazol-1-karboksamid (95); 4-(1-akriloil-1,2,5,6-tetrahidropiridin-3-il)-3-fluoro-9H-karbazol-1-karboksamid (96); (RS)-4-(1-akriloilpiperidin-3-il)-3-fluoro-9H-karbazol-1-karboksamid (97); 4-(1-akriloilpiperidin-3-il)-3-fluoro-9H-karbazol-1-karboksamid, pojedinačni enantiomeri (98 i 99); 3-fluoro-4-((2-vinilpiridin-4-il)metil)-9H-karbazol-1-karboksamid (100); 4-(1-akriloilpirolidin-3-il)-3-fluoro-9H-karbazol-1-karboksamid (112); 4-(1-akriloilpirolidin-3-il)-3-fluoro-9H-karbazol-1-karboksamid (113 i 114); cis-4-(1-(but-2-inoil)oktahidro-6H-pirolo[3,4-b]piridin-6-il)-3-fluoro-9H-karbazol-1-karboksamid (115); cis-4-(1-(but-2-inoil)oktahidro-6H-pirolo[3,4-b]piridin-6-il)-3-fluoro-9H-karbazol-1-karboksamid (116 i 117); (S)-4-(3-(but-2-inamido)piperidin-1-il)-3-fluoro-9H-karbazol-1-karboksamid (118); cis-4-(1-akriloiloktahidro-6H-pirolo[3,4-b]piridin-6-il)-3-fluoro-9H-karbazol-1-karboksamid (119); cis-4-(1-akriloiloktahidro-6H-pirolo[3,4-b]piridin-6-il)-3-fluoro-9H-karbazol-1-karboksamid (120 i 121); 3-fluoro-4-((2-vinilpirimidin-5-il)metil)-9H-karbazol-1-karboksamid (122); cis-4-(1-akriloilheksahidropirolo[3,4-b]pirol-5(1H)-il)-3-fluoro-9H-karbazol-1-karboksamid (123); cis-4-(1-akriloilheksahidropirolo[3,4-b]pirol-5(1H)-il)-3-fluoro-9H-karbazol-1-karboksamid (124 i 125); 4-(1-(but-2-inoil)oktahidro-6H-pirolo[3,4-b]piridin-6-il)-3-kloro-9H-karbazol-1-karboksamid (126); 4-((4aS,7aS)-1-(but-2-inoil)oktahidro-6H-pirolo[3,4-b]piridin-6-il)-3-kloro-9H-karbazol-1-karboksamid i 4-((4aR,7aR)-1-(but-2-inoil)oktahidro-6H-pirolo[3,4-b]piridin-6-il)-3-kloro-9H-karbazol-1-karboksamid (127 i 128); 3-fluoro-4-((2-(prop-1-in-1-il)piridin-4-il)metil)-9H-karbazol-1-karboksamid (129); 5-((S)-3-(but-2-inamido) piperidin-1-il)-6-fluoro-2-(2-hidroksipropan-2-il)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (130, 131, i 132); 4-(2-akriloilizoindolin-5-il)-3-fluoro-9H-karbazol-1-karboksamid (133); 4-(1-akriloil-2,5-dihidro-1H-pirol-3-il)-3-fluoro-9H-karbazol-1-karboksamid (134); 5-(1-akriloilpirolidin-3-il)-6-fluoro-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (135); (R)-4-(3-(but-2-inamido)piperidin-1-il)-3-fluoro-9H-karbazol-1-karboksamid (136); 4-(1-(but-2-inoil)heksahidropirolo[3,4-b]pirol-5(1H)-il)-3-fluoro-9H-karbazol-1-karboksamid (137); 4-(1-akriloil-1,4,5,6-tetrahidropiridin-3-il)-3-fluoro-9H-karbazol-1-karboksamid (138); 4-(7-(but-2-inoil)-2,7-diazaspiro[4.4] nonan-2-il)-3-fluoro-9H-karbazol-1-karboksamid (139); 4-(7-akriloil-2,7-diazaspiro [4.4]nonan-2-il)-3-fluoro-9H-karbazol-1-karboksamid (140); 4-(1-akriloiloktahidro-5H-pirolo[3,2-c]piridin-5-il)-3-fluoro-9H-karbazol-1-karboksamid (141); 4-(1-(but-2-inoil)oktahidro-5H-pirolo[3,2-c]piridin-5-il)-3-fluoro-9H-karbazol-1-karboksamid (142); 4-(6-akriloil-3,6-diazabiciklo[3.2.0]heptan-3-il)-3-fluoro-9H-karbazol-1-karboksamid (143); 4-(6-(but-2-inoil)-3,6-diazabiciklo[3.2.0] heptan-3-il)-3-fluoro-9H-karbazol-1-karboksamid (144); 4-(7-akriloiloktahidro-2,7-naftiridin-2(1H)-il)-3-fluoro-9H-karbazol-1-karboksamid (145); 4-(1-akriloiloktahidro-6H-pirolo[3,4-b] piridin-6-il)-3-kloro-9H-karbazol-1-karboksamid (146); 4-(1-(but-2-inoil)indolin-4-il)-3-fluoro-9H-karbazol-1-karboksamid (147); 4-(2-(but-2-inoil)-1,2,3,4-tetrahidroizohinolin-7-il)-3-fluoro-9H-karbazol-1-karboksamid (148); 4-(2-(but-2-inoil)-1,2,3,4-tetrahidroizohinolin-6-il)-3-fluoro-9H-karbazol-1-karboksamid (149); 4-(2-(but-2-inoil)izoindolin-4-il)-3-fluoro-9H-karbazol-1-karboksamid (150); 4-(1-(but-2-inoil)indolin-6-il)-3-fluoro-9H-karbazol-1-karboksamid (151); 3-fluoro-4-((6-vinilpirazin-2-il)metil)-9H-karbazol-1-karboksamid (152); 3-kloro-4-((6-vinilpirazin-2-il)metil)-9H-karbazol-1-karboksamid (153); 4-((6-etinilpiridin-3-il)metil)-3-fluoro-9H-karbazol-1-karboksamid (154); 3-kloro-4-((6-vinilpiridin-3-il)metil)-9H-karbazol-1-karboksamid (155); 4-((2-etinilpiridin-4-il)metil)-3-fluoro-9H-karbazol-1-karboksamid (156); 3-fluoro-4-((2-viniltiazol-5-il)metil)-9H-karbazol-1-karboksamid (157); 3-fluoro-4-((6-(prop-1-in-1-il)piridin-3-il)metil)-9H-karbazol-1-karboksamid (158); 3-fluoro-4-((5-vinilpirazin-2-il)metil)-9H-karbazol-1-karboksamid (159); 4-(1-akriloil-1,2,5,6-tetrahidropiridin-3-il)-3-fluoro-7-(trifluorometil)-9H-karbazol-1-karboksamid (160); 4-(1-akriloilpiperidin-3-il)-3-fluoro-7-(trifluorometil)-9H-karbazol-1-karboksamid (161 i 162); (S)-4-(3-akrilamidopiperidin-1-il)-3-fluoro-7-(trifluorometil)-9H-karbazol-1-karboksamid (163); (S)-4-(3-(but-2-inamido)piperidin-1-il)-3-fluoro-7-(trifluorometil)-9H-karbazol-1-karboksamid (164); (R)-4-(3-(but-2-inamido)piperidin-1-il)-3-fluoro-7-(trifluorometil)-9H-karbazol-1-karboksamid (165); (S)-4-(3-(3-ciklopropilpropiolamido)piperidin-1-il)-3-fluoro-7-(trifluorometil)-9H-karbazol-1-karboksamid (166); (S)-4-(3-cijanamidopiperidin-1-il)-3-fluoro-7-(trifluorometil)-9H-karbazol-1-karboksamid (167); 4-(2-akriloilizoindolin-4-il)-3-fluoro-7-(trifluorometil)-9H-karbazol-1-karboksamid (168); 4-(1-akriloilindolin-4-il)-3-fluoro-7-(trifluorometil)-9H-karbazol-1-karboksamid (169); 4-(1-akriloilindolin-6-il)-3-fluoro-7-(trifluorometil)-9H-karbazol-1-karboksamid (170); 4-(1-akriloil-1-azaspiro[4.4]nonan-7-il)-3-fluoro-7-(trifluorometil)-9H-karbazol-1-karboksamid (171); (S)-4-(3-(but-2-inamido)piperidin-1-il)-3-fluoro-7-(4-metilpiperazin-1-karbonil)-9H-karbazol-1-karboksamid (172); (S)-4-(3-(but-2-inamido)piperidin-1-il)-3-fluoro-N7,N7-dimetil-9H-karbazol-1,7-dikarboksamid (173); 3-fluoro-N7,N7-dimetil-4-(2-vinilpiridin-4-il)-9H-karbazol-1,7-dikarboksamid (174); (S)-4-((1-cijanopirolidin-3-il)amino)-3-fluoro-N7,N7-dimetil-9H-karbazol-1,7-dikarboksamid (175); (S)-4-((1-cijanopirolidin-3-il)amino)-3-fluoro-7-(4-metilpiperazin-1-karbonil)-9H-karbazol-1-karboksamid (176); 4-(2-akriloil-1,2,3,4-tetrahidroizohinolin-5-il)-7-(morfolin-4-karbonil)-9H-karbazol-1-karboksamid (177); 4-(2-(but-2-inoil)-1,2,3,4-tetrahidroizohinolin-5-il)-7-(morfolin-4-karbonil)-9H-karbazol-1-karboksamid (178); 4-(2-cijano-1,2,3,4-tetrahidroizohinolin-5-il)-7-(morfolin-4-karbonil)-9H-karbazol-1-karboksamid (179); 4-(1-akriloilindolin-6-il)-3-fluoro-7-(2-hidroksietil)-9H-karbazol-1-karboksamid (180); 4-(1-cijanoindolin-6-il)-3-fluoro-7-(2-hidroksietil)-9H-karbazol-1-karboksamid (181); 4-(1-akriloiloktahidro-6H-pirolo[3,4-b]piridin-6-il)-6-kloro-3-fluoro-9H-karbazol-1-karboksamid (182); 4-(1-(but-2-inoil)oktahidro-6H-pirolo[3,4-b]piridin-6-il)-6-kloro-3-fluoro-9H-karbazol-1-karboksamid (183); 5-(1-akriloil-1,2,5,6-tetrahidropiridin-3-il)-6-fluoro-2-(2-hidroksipropan-2-il)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (184); (R)-6-fluoro-2-(2-hidroksipropan-2-il)-5-((6-vinilpiridin-3-il)metil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (185); 5-(2-akriloil-1,2,3,4-tetrahidroizohinolin-5-il)-6-fluoro-2-(2-hidroksipropan-2-il)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (186 i 187); 6-fluoro-2-(2-hidroksipropan-2-il)-5-((6-(prop-1-in-1-il)piridin-3-il)metil)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (188); 3-fluoro-4-(2-vinilpiridin-4-il)-9H-karbazol-1-karboksamid (189); 4-(7-(but-2-inoil)oktahidro-2,7-naftiridin-2(1H)-il)-3-fluoro-9H-karbazol-1-karboksamid (190); 4-(1-akriloil-1,2,3,6-tetrahidropiridin-4-il)-3-fluoro-9H-karbazol-1-karboksamid (191); 4-(1-(but-2-inoil)-1,2,3,6-tetrahidropiridin-4-il)-3-fluoro-9H-karbazol-1-karboksamid (192); 3-fluoro-4-(5-(N-metilakrilamido)piridin-2-il)-9H-karbazol-1-karboksamid (193); 4-((1S,4S)-2-akriloil-2-azabiciklo[2.2.1]heptan-5-il)-3-fluoro-9H-karbazol-1-karboksamid (194); 3-fluoro-4-((2-metil-6-vinilpiridin-4-il)metil)-9H-karbazol-1-karboksamid (195); 3-fluoro-4-((2-metil-6-vinilpirimidin-4-il)metil)-9H-karbazol-1-karboksamid (196); 3-fluoro-4-((4-metil-6-vinilpirimidin-2-il)metil)-9H-karbazol-1-karboksamid (197); 3-fluoro-4-((3-fluoro-2-vinilpiridin-4-il)metil)-9H-karbazol-1-karboksamid (198); 4-(3-(1-akriloilpirolidin-2-il)fenil)-3-fluoro-9H-karbazol-1-karboksamid (199); 4-(3-(1-(but-2-inoil)pirolidin-2-il)fenil)-3-fluoro-9H-karbazol-1-karboksamid (200); (E)-3-fluoro-4-(3-(3-morfolino-3-oksoprop-1-en-1-il)fenil)-9H-karbazol-1-karboksamid (201); (E)-3-fluoro-4-(3-(3-okso-3-(pirolidin-1-il)prop-1-en-1-il)fenil)-9H-karbazol-1-karboksamid (202); ili 5-(2-akriloil-1,2,3,4-tetrahidroizohinolin-5-il)-2-(2-hidroksipropan-2-il)-2,3,4,9-tetrahidro-1H-karbazol-8-karboksamid (203 i 204). 12. A compound according to claim 1 or a salt thereof, wherein the compound is: (RS)-5-(3-acrylamidophenyl)-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro- 1H-carbazole-8-carboxamide (1); (RS)-2-(2-hydroxypropan-2-yl)-5-(2-methyl-3-(N-methylvinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (2); 5-(3-acrylamido-2-methylphenyl)-2,2-dimethyl-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (3); 4-(3-acrylamido-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9H-carbazole-1-carboxamide (4); (RS)-2-(2-hydroxypropan-2-yl)-5-(3-(vinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (5); (RS)-4-(3-acrylamido-2-methylphenyl)-3-chloro-7-(2-hydroxypropan-2-yl)-9H-carbazole-1-carboxamide (6); 5-(3-acrylamido-2-methylphenyl)-2-(hydroxymethyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (7); (RS)-5-(3-acrylamido-2-methylphenyl)-6-chloro-2-(hydroxymethyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide, mixture of diastereomers (8); 5-(3-acrylamido-2-methylphenyl)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2,8-dicarboxamide, mixture of diastereomers (9); (RS)-5-(3-acrylamido-2-methylphenyl)-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (10); (RS)-(E)-4-(3-(but-2-enamido)-2-methylphenyl)-3-chloro-7-(2-hydroxypropan-2-yl)-9H-carbazole-1-carboxamide ( 11); 5-(3-acrylamido-2-methylphenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (12); (RS)-2-(2-hydroxypropan-2-yl)-5-(2-methyl-3-(vinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (13 ); (RS)-5-(3-acrylamido-2-methylphenyl)-2,3,4,9-tetrahydro-1H-carbazole-2,8-dicarboxamide (14); 4-(3-acrylamido-2-methylphenyl)-7-cyano-9H-carbazole-1-carboxamide (15); (RS)-4-(3-acrylamido-2-methylphenyl)-7-(1,2-dihydroxyethyl)-9H carbazole-1-carboxamide (16); 4-(3-acrylamido-2-methylphenyl)-7-(isopropylamino)-9H-carbazole-1-carboxamide (17); (RS)-5-(3-acrylamido-2-methylphenyl)-N2,N2-dimethyl-2,3,4,9-tetrahydro-1H-carbazole-2,8-dicarboxamide (18); (RS)-2-(2-hydroxypropan-2-yl)-5-(2-methyl-3-(N-methylacrylamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (19); (RS)-2-(hydroxymethyl)-5-(2-methyl-3-(N-methylacrylamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (20); (RS)-N2,N2-dimethyl-5-(2-methyl-3-(N-methylacrylamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-2,8-dicarboxamide (21); (2R)-6-fluoro-2-(2-hydroxypropan-2-yl)-5-(2-methyl-3-(N-methylvinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole -8-carboxamide, mixture of diastereomers (22); (2R)-6-chloro-2-(2-hydroxypropan-2-yl)-5-(2-methyl-3-(N-methylvinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole -8-carboxamide, mixture of diastereomers (23); (2R)-6-fluoro-2-(2-hydroxypropan-2-yl)-5-(3-(N-methylvinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide , one enantiomer (24); (2R)-6-chloro-2-(2-hydroxypropan-2-yl)-5-(3-(N-methylvinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide , one enantiomer (25); (RS)-2-(2-hydroxypropan-2-yl)-5-(3-(N-methylvinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (26); 7-(2-hydroxypropan-2-yl)-4-(2-methyl-3-(N-methylvinylsulfonamido)phenyl)-9H-carbazole-1-carboxamide (27); 7-(2-hydroxypropan-2-yl)-4-(3-(N-methylvinylsulfonamido)phenyl)-9H-carbazole-1-carboxamide (28); (RS)-3-fluoro-7-(2-hydroxypropan-2-yl)-4-(2-methyl-3-(vinylsulfonamido)phenyl)-9H-carbazole-1-carboxamide (29); (RS)-3-fluoro-7-(2-hydroxypropan-2-yl)-4-(2-methyl-3-(N-methylvinylsulfonamido)phenyl)-9H-carbazole-1-carboxamide (30); 3-fluoro-7-(2-hydroxypropan-2-yl)-4-(3-(N-methylvinylsulfonamido)phenyl)-9H-carbazole-1-carboxamide (31); 7-(2-hydroxypropan-2-yl)-4-(2-methyl-3-(vinylsulfonamido)phenyl)-9H-carbazole-1-carboxamide (32); 7-(2-hydroxypropan-2-yl)-4-(3-(vinylsulfonamido)phenyl)-9H-carbazole-1-carboxamide (33); 3-fluoro-7-(2-hydroxypropan-2-yl)-4-(3-(vinylsulfonamido)phenyl)-9H-carbazole-1-carboxamide (34); (RS)-2-(2-hydroxypropan-2-yl)-5-(3-(N-methylacrylamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (35); (R)-6-fluoro-2-(2-hydroxypropan-2-yl)-5-(3-(N-methylacrylamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (36); 7-(2-hydroxypropan-2-yl)-4-(3-(N-methylacrylamido)phenyl)-9H-carbazole-1-carboxamide (37); 3-fluoro-7-(2-hydroxypropan-2-yl)-4-(3-(N-methylacrylamido)phenyl)-9H-carbazole-1-carboxamide (38); (R)-6-chloro-2-(2-hydroxypropan-2-yl)-5-(3-(N-methylacrylamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (39); (S)-2-(2-hydroxypropan-2-yl)-5-(3-(vinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (40); (R)-2-(2-hydroxypropan-2-yl)-5-(3-(vinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (41); (RS)-5-(2-fluoro-3-(N-methylacrylamido)phenyl)-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (42); (R)-6-fluoro-2-(2-hydroxypropan-2-yl)-5-(3-(vinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (43 ); (2R)-6-chloro-2-(2-hydroxypropan-2-yl)-5-(2-methyl-3-(vinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8 -carboxamide, mixture of diastereomers (44); (RS)-5-(2-fluoro-3-(N-methylvinylsulfonamido)phenyl)-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (45); (RS)-5-(2-chloro-3-(N-methylvinylsulfonamido)phenyl)-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (46); (2R)-6-fluoro-2-(2-hydroxypropan-2-yl)-5-(2-methyl-3-(vinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8 -carboxamide, mixture of diastereomers (47); 5-(3-(vinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (48); 5-(2-methyl-3-(vinylsulfonamido)phenyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (49); (RS)-5-(3-acrylamido-4-methoxyphenyl)-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (50); (RS)-5-(3-acrylamido-4-(trifluoromethoxy)phenyl)-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (51 ); (RS)-5-(3-acrylamido-4-fluorophenyl)-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (52); (RS)-5-(3-acrylamido-2-methylphenyl)-2-methyl-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (53); (RS)-5-(3-acrylamido-2-methylphenyl)-2-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (54); 5-(3-acrylamido-2-methylphenyl)-6-chloro-2-(hydroxymethyl)-2-methyl-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide, individual racemic diastereomers (55 and 56); 5-(3-acrylamido-2-methylphenyl)-6-chloro-N2,N2-dimethyl-2,3,4,9-tetrahydro-1H-carbazole-2,8-dicarboxamide, individual racemic diastereomers (57 and 58) ; 5-(3-acrylamido-2-methylphenyl)-6-chloro-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide, individual racemic diastereomers ( 59 and 60); 5-(3-acrylamido-2-methylphenyl)-6-chloro-2-(2-hydroxypropan-2-yl)-2-methyl-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide, individual racemic diastereomers (61 and 62); (S)-5-((1-acryloylpyrrolidin-3-yl)amino)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (63); (E)-4-(3-(but-2-enamido)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9H-carbazole-1-carboxamide (64); 5-(((S)-1-acryloylpyrrolidin-3-yl)amino)-2-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide, mixture of diastereomers (65); (S)-5-(3-acrylamidopiperidin-1-yl)-3,3,6-trifluoro-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (66); (S)-4-(3-acrylamidopiperidin-1-yl)-3-fluoro-9H-carbazole-1-carboxamide (69); 5-(((S)-1-propioloylpyrrolidin-3-yl)amino)-2-(RS)-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide, mixture of diastereomers ( 72); (S)-5-(3-(but-2-inamido)piperidin-1-yl)-3,3,6-trifluoro-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (73 ); (S)-3-fluoro-4-(3-(N-methylbut-2-inamido)piperidin-1-yl)-9H-carbazole-1-carboxamide (74); (S)-4-(3-(but-2-inamido)piperidin-1-yl)-3-fluoro-9H-carbazole-1-carboxamide (75); (S)-4-(3-(3-cyclopropylpropiolamido)piperidin-1-yl)-3-fluoro-9H-carbazole-1-carboxamide (76); 5-(((S)-1-acryloylpyrrolidin-3-yl)amino)-2-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide, individual diastereomers (77 and 78) ; 3-fluoro-4-((6-vinylpyridin-3-yl)methyl)-9H-carbazole-1-carboxamide (87); (RS)-4-(2-acryloylisoindolin-4-yl)-3-fluoro-9H-carbazole-1-carboxamide (89); 4-(2-acryloyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluoro-9H-carbazole-1-carboxamide (90); 4-(2-acryloyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-3-fluoro-9H-carbazole-1-carboxamide (91); 4-(1-acryloylindolin-4-yl)-3-fluoro-9H-carbazole-1-carboxamide (92); 4-(1-acryloylindolin-6-yl)-3-fluoro-9H-carbazole-1-carboxamide (95); 4-(1-acryloyl-1,2,5,6-tetrahydropyridin-3-yl)-3-fluoro-9H-carbazole-1-carboxamide (96); (RS)-4-(1-acryloylpiperidin-3-yl)-3-fluoro-9H-carbazole-1-carboxamide (97); 4-(1-acryloylpiperidin-3-yl)-3-fluoro-9H-carbazole-1-carboxamide, single enantiomers (98 and 99); 3-fluoro-4-((2-vinylpyridin-4-yl)methyl)-9H-carbazole-1-carboxamide (100); 4-(1-acryloylpyrrolidin-3-yl)-3-fluoro-9H-carbazole-1-carboxamide (112); 4-(1-acryloylpyrrolidin-3-yl)-3-fluoro-9H-carbazole-1-carboxamide (113 and 114); cis-4-(1-(but-2-inoyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluoro-9H-carbazole-1-carboxamide (115); cis-4-(1-(but-2-inoyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluoro-9H-carbazole-1-carboxamide (116 and 117); (S)-4-(3-(but-2-inamido)piperidin-1-yl)-3-fluoro-9H-carbazole-1-carboxamide (118); cis-4-(1-acryloyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluoro-9H-carbazole-1-carboxamide (119); cis-4-(1-acryloyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluoro-9H-carbazole-1-carboxamide (120 and 121); 3-fluoro-4-((2-vinylpyrimidin-5-yl)methyl)-9H-carbazole-1-carboxamide (122); cis-4-(1-acryloylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-3-fluoro-9H-carbazole-1-carboxamide (123); cis-4-(1-Acryloylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-3-fluoro-9H-carbazole-1-carboxamide (124 and 125); 4-(1-(but-2-inoyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-chloro-9H-carbazole-1-carboxamide (126); 4-((4aS,7aS)-1-(but-2-inoyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-chloro-9H-carbazole-1-carboxamide and 4 -((4aR,7aR)-1-(but-2-inoyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-chloro-9H-carbazole-1-carboxamide (127 and 128); 3-fluoro-4-((2-(prop-1-yn-1-yl)pyridin-4-yl)methyl)-9H-carbazole-1-carboxamide (129); 5-((S)-3-(but-2-inamido)piperidin-1-yl)-6-fluoro-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H -carbazole-8-carboxamide (130, 131, and 132); 4-(2-acryloylisoindolin-5-yl)-3-fluoro-9H-carbazole-1-carboxamide (133); 4-(1-acryloyl-2,5-dihydro-1H-pyrrol-3-yl)-3-fluoro-9H-carbazole-1-carboxamide (134); 5-(1-acryloylpyrrolidin-3-yl)-6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (135); (R)-4-(3-(but-2-inamido)piperidin-1-yl)-3-fluoro-9H-carbazole-1-carboxamide (136); 4-(1-(but-2-inoyl)hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-3-fluoro-9H-carbazole-1-carboxamide (137); 4-(1-acryloyl-1,4,5,6-tetrahydropyridin-3-yl)-3-fluoro-9H-carbazole-1-carboxamide (138); 4-(7-(but-2-inoyl)-2,7-diazaspiro[4.4]nonan-2-yl)-3-fluoro-9H-carbazole-1-carboxamide (139); 4-(7-acryloyl-2,7-diazaspiro [4.4]nonan-2-yl)-3-fluoro-9H-carbazole-1-carboxamide (140); 4-(1-acryloyloctahydro-5H-pyrrolo[3,2-c]pyridin-5-yl)-3-fluoro-9H-carbazole-1-carboxamide (141); 4-(1-(but-2-inoyl)octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl)-3-fluoro-9H-carbazole-1-carboxamide (142); 4-(6-acryloyl-3,6-diazabicyclo[3.2.0]heptan-3-yl)-3-fluoro-9H-carbazole-1-carboxamide (143); 4-(6-(but-2-inoyl)-3,6-diazabicyclo[3.2.0]heptan-3-yl)-3-fluoro-9H-carbazole-1-carboxamide (144); 4-(7-acryloyloctahydro-2,7-naphthyridin-2(1H)-yl)-3-fluoro-9H-carbazole-1-carboxamide (145); 4-(1-acryloyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-chloro-9H-carbazole-1-carboxamide (146); 4-(1-(but-2-inoyl)indolin-4-yl)-3-fluoro-9H-carbazole-1-carboxamide (147); 4-(2-(but-2-inoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluoro-9H-carbazole-1-carboxamide (148); 4-(2-(but-2-inoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-3-fluoro-9H-carbazole-1-carboxamide (149); 4-(2-(but-2-inoyl)isoindolin-4-yl)-3-fluoro-9H-carbazole-1-carboxamide (150); 4-(1-(but-2-inoyl)indolin-6-yl)-3-fluoro-9H-carbazole-1-carboxamide (151); 3-fluoro-4-((6-vinylpyrazin-2-yl)methyl)-9H-carbazole-1-carboxamide (152); 3-chloro-4-((6-vinylpyrazin-2-yl)methyl)-9H-carbazole-1-carboxamide (153); 4-((6-ethynylpyridin-3-yl)methyl)-3-fluoro-9H-carbazole-1-carboxamide (154); 3-chloro-4-((6-vinylpyridin-3-yl)methyl)-9H-carbazole-1-carboxamide (155); 4-((2-ethynylpyridin-4-yl)methyl)-3-fluoro-9H-carbazole-1-carboxamide (156); 3-fluoro-4-((2-vinylthiazol-5-yl)methyl)-9H-carbazole-1-carboxamide (157); 3-fluoro-4-((6-(prop-1-yn-1-yl)pyridin-3-yl)methyl)-9H-carbazole-1-carboxamide (158); 3-fluoro-4-((5-vinylpyrazin-2-yl)methyl)-9H-carbazole-1-carboxamide (159); 4-(1-acryloyl-1,2,5,6-tetrahydropyridin-3-yl)-3-fluoro-7-(trifluoromethyl)-9H-carbazole-1-carboxamide (160); 4-(1-acryloylpiperidin-3-yl)-3-fluoro-7-(trifluoromethyl)-9H-carbazole-1-carboxamide (161 and 162); (S)-4-(3-acrylamidopiperidin-1-yl)-3-fluoro-7-(trifluoromethyl)-9H-carbazole-1-carboxamide (163); (S)-4-(3-(but-2-inamido)piperidin-1-yl)-3-fluoro-7-(trifluoromethyl)-9H-carbazole-1-carboxamide (164); (R)-4-(3-(but-2-inamido)piperidin-1-yl)-3-fluoro-7-(trifluoromethyl)-9H-carbazole-1-carboxamide (165); (S)-4-(3-(3-cyclopropylpropiolamido)piperidin-1-yl)-3-fluoro-7-(trifluoromethyl)-9H-carbazole-1-carboxamide (166); (S)-4-(3-cyanamidopiperidin-1-yl)-3-fluoro-7-(trifluoromethyl)-9H-carbazole-1-carboxamide (167); 4-(2-acryloylisoindolin-4-yl)-3-fluoro-7-(trifluoromethyl)-9H-carbazole-1-carboxamide (168); 4-(1-acryloylindolin-4-yl)-3-fluoro-7-(trifluoromethyl)-9H-carbazole-1-carboxamide (169); 4-(1-acryloylindolin-6-yl)-3-fluoro-7-(trifluoromethyl)-9H-carbazole-1-carboxamide (170); 4-(1-acryloyl-1-azaspiro[4.4]nonan-7-yl)-3-fluoro-7-(trifluoromethyl)-9H-carbazole-1-carboxamide (171); (S)-4-(3-(but-2-inamido)piperidin-1-yl)-3-fluoro-7-(4-methylpiperazine-1-carbonyl)-9H-carbazole-1-carboxamide (172); (S)-4-(3-(but-2-inamido)piperidin-1-yl)-3-fluoro-N7,N7-dimethyl-9H-carbazole-1,7-dicarboxamide (173); 3-fluoro-N7,N7-dimethyl-4-(2-vinylpyridin-4-yl)-9H-carbazole-1,7-dicarboxamide (174); (S)-4-((1-cyanopyrrolidin-3-yl)amino)-3-fluoro-N7,N7-dimethyl-9H-carbazole-1,7-dicarboxamide (175); (S)-4-((1-cyanopyrrolidin-3-yl)amino)-3-fluoro-7-(4-methylpiperazine-1-carbonyl)-9H-carbazole-1-carboxamide (176); 4-(2-acryloyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-7-(morpholine-4-carbonyl)-9H-carbazole-1-carboxamide (177); 4-(2-(but-2-inoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)-7-(morpholine-4-carbonyl)-9H-carbazole-1-carboxamide (178); 4-(2-cyano-1,2,3,4-tetrahydroisoquinolin-5-yl)-7-(morpholine-4-carbonyl)-9H-carbazole-1-carboxamide (179); 4-(1-acryloylindolin-6-yl)-3-fluoro-7-(2-hydroxyethyl)-9H-carbazole-1-carboxamide (180); 4-(1-cyanoindolin-6-yl)-3-fluoro-7-(2-hydroxyethyl)-9H-carbazole-1-carboxamide (181); 4-(1-acryloyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-6-chloro-3-fluoro-9H-carbazole-1-carboxamide (182); 4-(1-(but-2-inoyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-6-chloro-3-fluoro-9H-carbazole-1-carboxamide (183); 5-(1-acryloyl-1,2,5,6-tetrahydropyridin-3-yl)-6-fluoro-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H- carbazole-8-carboxamide (184); (R)-6-fluoro-2-(2-hydroxypropan-2-yl)-5-((6-vinylpyridin-3-yl)methyl)-2,3,4,9-tetrahydro-1H-carbazole-8 -carboxamide (185); 5-(2-acryloyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-6-fluoro-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H- carbazole-8-carboxamide (186 and 187); 6-fluoro-2-(2-hydroxypropan-2-yl)-5-((6-(prop-1-yn-1-yl)pyridin-3-yl)methyl)-2,3,4,9- tetrahydro-1H-carbazole-8-carboxamide (188); 3-fluoro-4-(2-vinylpyridin-4-yl)-9H-carbazole-1-carboxamide (189); 4-(7-(but-2-inoyl)octahydro-2,7-naphthyridin-2(1H)-yl)-3-fluoro-9H-carbazole-1-carboxamide (190); 4-(1-acryloyl-1,2,3,6-tetrahydropyridin-4-yl)-3-fluoro-9H-carbazole-1-carboxamide (191); 4-(1-(but-2-inoyl)-1,2,3,6-tetrahydropyridin-4-yl)-3-fluoro-9H-carbazole-1-carboxamide (192); 3-Fluoro-4-(5-(N-methylacrylamido)pyridin-2-yl)-9H-carbazole-1-carboxamide (193); 4-((1S,4S)-2-acryloyl-2-azabicyclo[2.2.1]heptan-5-yl)-3-fluoro-9H-carbazole-1-carboxamide (194); 3-fluoro-4-((2-methyl-6-vinylpyridin-4-yl)methyl)-9H-carbazole-1-carboxamide (195); 3-fluoro-4-((2-methyl-6-vinylpyrimidin-4-yl)methyl)-9H-carbazole-1-carboxamide (196); 3-fluoro-4-((4-methyl-6-vinylpyrimidin-2-yl)methyl)-9H-carbazole-1-carboxamide (197); 3-fluoro-4-((3-fluoro-2-vinylpyridin-4-yl)methyl)-9H-carbazole-1-carboxamide (198); 4-(3-(1-acryloylpyrrolidin-2-yl)phenyl)-3-fluoro-9H-carbazole-1-carboxamide (199); 4-(3-(1-(but-2-inoyl)pyrrolidin-2-yl)phenyl)-3-fluoro-9H-carbazole-1-carboxamide (200); (E)-3-fluoro-4-(3-(3-morpholino-3-oxoprop-1-en-1-yl)phenyl)-9H-carbazole-1-carboxamide (201); (E)-3-fluoro-4-(3-(3-oxo-3-(pyrrolidin-1-yl)prop-1-en-1-yl)phenyl)-9H-carbazole-1-carboxamide (202) ; or 5-(2-acryloyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8 -carboxamide (203 and 204). 13. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, gdje je navedeno spoj: (S)-4-(3-(but-2-inamido)piperidin-1-il)-3-fluoro-9H-karbazol-1-karboksamid.13. A compound according to claim 1 or its salt, wherein the compound is: (S)-4-(3-(but-2-inamido)piperidin-1-yl)-3-fluoro-9H-carbazole-1 -carboxamide. 14. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, gdje je navedeno spoj: 3-fluoro-4-((2-vinilpiridin-4-il)metil)-9H-karbazol-1-karboksamid.14. A compound according to claim 1 or its salt, wherein the compound is: 3-fluoro-4-((2-vinylpyridin-4-yl)methyl)-9H-carbazole-1-carboxamide. 15. Spoj u skladu sa patentnim zahtjevom 1 ili njegova sol, gdje je navedeno spoj: cis-4-(1-(but-2-inoil)oktahidro-6H-pirolo[3,4-b]piridin-6-il)-3-fluoro-9H-karbazol-1-karboksamid.15. A compound according to claim 1 or its salt, wherein the compound is: cis-4-(1-(but-2-inoyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl) -3-fluoro-9H-carbazole-1-carboxamide. 16. Farmaceutska kompozicija koja sadrži spoj u skladu sa bilo kojim od patentnih zahtjeva 2-9 ili 13-15 i farmaceutski prihvatljiv nosač.16. A pharmaceutical composition containing a compound according to any of claims 2-9 or 13-15 and a pharmaceutically acceptable carrier. 17. Spoj u skladu sa bilo kojim od patentnih zahtjeva 9 ili 13-15, za primjenu u terapiji.17. A compound according to any of claims 9 or 13-15, for use in therapy. 18. Spoj u skladu sa bilo kojim od patentnih zahtjeva 2-9 ili 13-15 za primjenu u terapiji u liječenju autoimune bolesti ili kronične inflamatorne bolesti.18. A compound according to any one of patent claims 2-9 or 13-15 for use in therapy in the treatment of an autoimmune disease or a chronic inflammatory disease.
HRP20192197TT 2014-10-24 2015-10-23 CARBAZOLE DERIVATIVES HRP20192197T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068234P 2014-10-24 2014-10-24
EP15790408.7A EP3209651B9 (en) 2014-10-24 2015-10-23 Carbazole derivatives
PCT/US2015/057077 WO2016065236A1 (en) 2014-10-24 2015-10-23 Carbazole derivatives

Publications (3)

Publication Number Publication Date
HRP20192197T1 HRP20192197T1 (en) 2020-03-06
HRP20192197T8 HRP20192197T8 (en) 2020-04-03
HRP20192197T2 true HRP20192197T2 (en) 2020-11-13

Family

ID=54427879

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20192197TT HRP20192197T2 (en) 2014-10-24 2015-10-23 CARBAZOLE DERIVATIVES

Country Status (34)

Country Link
US (3) US10266491B2 (en)
EP (1) EP3209651B9 (en)
JP (1) JP6599983B2 (en)
KR (1) KR102514914B1 (en)
CN (1) CN107074804B (en)
AR (1) AR102427A1 (en)
AU (1) AU2015335703B2 (en)
BR (1) BR112017007545A2 (en)
CA (1) CA2965523A1 (en)
CL (1) CL2017001001A1 (en)
CO (1) CO2017004517A2 (en)
CY (1) CY1122549T1 (en)
DK (1) DK3209651T3 (en)
EA (1) EA032361B1 (en)
ES (1) ES2761903T3 (en)
HR (1) HRP20192197T2 (en)
HU (1) HUE048321T2 (en)
IL (1) IL251798B (en)
LT (1) LT3209651T (en)
MA (1) MA40302B1 (en)
ME (1) ME03754B (en)
MX (1) MX374724B (en)
MY (1) MY190568A (en)
PE (1) PE20171239A1 (en)
PH (1) PH12017500724B1 (en)
PL (1) PL3209651T3 (en)
PT (1) PT3209651T (en)
RS (1) RS59707B1 (en)
SG (2) SG10201903619YA (en)
SI (1) SI3209651T1 (en)
SM (1) SMT202000035T1 (en)
TN (1) TN2017000158A1 (en)
TW (1) TWI676618B (en)
WO (1) WO2016065236A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6592512B2 (en) * 2014-10-24 2019-10-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Tricyclic atropisomeric compounds
SG11201702312UA (en) 2014-10-24 2017-05-30 Takeda Pharmaceuticals Co Heterocyclic compound
JP6726773B2 (en) * 2016-07-07 2020-07-22 デウン ファーマシューティカル カンパニー リミテッド Novel 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivative and pharmaceutical composition containing the same
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
WO2019075386A1 (en) 2017-10-13 2019-04-18 The Regents Of The University Of California Mtorc1 modulators
CN109053542A (en) * 2018-07-25 2018-12-21 南通大学 A kind of chemical synthesis process of the bromo- 5- hydroxyl 1-isoindolinone of 6-
ES2965164T3 (en) * 2019-10-04 2024-04-11 Bristol Myers Squibb Co Substituted carbazole compounds
CN110862396B (en) * 2019-11-29 2021-06-04 浙江工业大学 A kind of synthetic method of pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione compound
CA3174838A1 (en) * 2020-04-10 2021-10-14 Craig Alan Coburn Kinase inhibitors
JP2023528421A (en) * 2020-06-02 2023-07-04 ジービー００５， インコーポレイテッド Kinase inhibitor
CN115232061B (en) * 2021-09-18 2024-01-30 山西紫罗蓝新材料科技有限公司 Extraction process of 3-nitro-9-ethylcarbazole crude product
TW202408487A (en) * 2022-07-06 2024-03-01 美商維維迪昂醫療公司 Pharmaceutical compositions comprising wrn helicase inhibitors
EP4594308A1 (en) * 2022-09-29 2025-08-06 Vividion Therapeutics, Inc. N-acryloylmorpholine derivatives as keap1 modulators and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
DE602005023333D1 (en) 2004-10-15 2010-10-14 Takeda Pharmaceutical KINASE INHIBITORS
WO2006053121A2 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
AU2005315319B2 (en) 2004-12-17 2011-07-07 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CA2630562C (en) * 2005-11-22 2013-12-31 Merck & Co., Inc. Tricyclic compounds useful as inhibitors of kinases
MX2009002657A (en) 2006-09-11 2009-08-18 Matrix Lab Ltd Dibenzofuran derivatives as inhibitors of pde-4 and pde-10.
WO2008033858A2 (en) 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2231143B1 (en) * 2007-12-13 2013-07-03 Merck Sharp & Dohme Corp. 5H-pyrido[4,3-b]indoles as INHIBITORS OF JANUS KINASES
PL2247558T5 (en) 2008-02-14 2024-10-14 Eli Lilly And Company Novel imaging agents for detecting neurological dysfunction
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
JP2011524893A (en) 2008-06-18 2011-09-08 ファイザー・リミテッド Nicotinamide derivatives
DK2361248T3 (en) 2008-06-27 2019-01-14 Celgene Car Llc Heteroberl compounds and uses thereof
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
NZ593096A (en) * 2008-12-19 2012-11-30 Bristol Myers Squibb Co Carbazole carboxamide compounds useful as kinase inhibitors
CN101475571B (en) 2009-01-21 2011-06-22 中国药科大学 β-carboline cyclin-dependent kinase 2 inhibitors and uses thereof
WO2010093949A2 (en) 2009-02-13 2010-08-19 Nextivity, Inc. Remote control for booster
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
CN105330675A (en) 2010-11-15 2016-02-17 Viiv保健英国有限公司 Inhibitors of HIV replication
KR101585753B1 (en) 2011-05-17 2016-01-14 에프. 호프만-라 로슈 아게 Inhibitors of bruton's tyrosine kinase
JP6126131B2 (en) 2012-01-10 2017-05-10 ニンバス アイリス， インコーポレイテッド IRAK inhibitors and uses thereof
BR112015007513A2 (en) 2012-10-26 2017-07-04 Hoffmann La Roche bruton tyrosine kinase inhibitors
TWI648272B (en) * 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 Substituted tetrahydrocarbazole and carbazole carbamide compounds
CN105473573B (en) * 2013-06-25 2018-03-16 百时美施贵宝公司 Carbazole carboxamide compounds useful as kinase inhibitor
JP6592512B2 (en) * 2014-10-24 2019-10-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Tricyclic atropisomeric compounds
LT3209656T (en) 2014-10-24 2020-07-27 Bristol-Myers Squibb Company Indole carboxamides compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
EA032361B1 (en) 2019-05-31
JP6599983B2 (en) 2019-10-30
US20200255377A1 (en) 2020-08-13
CA2965523A1 (en) 2016-04-28
EP3209651B1 (en) 2019-10-23
EA201790745A1 (en) 2017-08-31
SG10201903619YA (en) 2019-05-30
CO2017004517A2 (en) 2017-08-31
KR20170075756A (en) 2017-07-03
EP3209651A1 (en) 2017-08-30
TN2017000158A1 (en) 2018-10-19
LT3209651T (en) 2020-01-10
MA40302A1 (en) 2018-05-31
AU2015335703A1 (en) 2017-06-08
KR102514914B1 (en) 2023-03-27
ES2761903T3 (en) 2020-05-21
MX2017005255A (en) 2017-08-18
US11053197B2 (en) 2021-07-06
MX374724B (en) 2025-03-06
HRP20192197T1 (en) 2020-03-06
TWI676618B (en) 2019-11-11
MA40302B1 (en) 2018-10-31
SG11201703187PA (en) 2017-05-30
US20170362176A1 (en) 2017-12-21
PE20171239A1 (en) 2017-08-24
US10266491B2 (en) 2019-04-23
PT3209651T (en) 2019-12-30
AR102427A1 (en) 2017-03-01
PH12017500724B1 (en) 2023-07-05
PL3209651T3 (en) 2020-03-31
AU2015335703B2 (en) 2020-05-21
US20190225583A1 (en) 2019-07-25
US10676434B2 (en) 2020-06-09
PH12017500724A1 (en) 2017-10-09
BR112017007545A2 (en) 2017-12-19
CL2017001001A1 (en) 2017-11-24
HUE048321T2 (en) 2020-07-28
WO2016065236A1 (en) 2016-04-28
RS59707B1 (en) 2020-01-31
JP2017535536A (en) 2017-11-30
CN107074804B (en) 2020-02-18
HRP20192197T8 (en) 2020-04-03
SI3209651T1 (en) 2019-12-31
EP3209651B9 (en) 2020-05-20
SMT202000035T1 (en) 2020-03-13
MY190568A (en) 2022-04-27
CN107074804A (en) 2017-08-18
ME03754B (en) 2021-04-20
TW201629014A (en) 2016-08-16
IL251798B (en) 2020-08-31
CY1122549T1 (en) 2021-01-27
DK3209651T3 (en) 2020-02-03
IL251798A0 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
HRP20192197T2 (en) CARBAZOLE DERIVATIVES
JP2017535536A5 (en)
JP7323723B2 (en) 2-Oxoimidazolidine-4-carboxamides as NAV1.8 inhibitors
IL320682A (en) Protein tyrosine phosphatase inhibitors
US11820766B2 (en) Monoacylglycerol lipase modulators
US10072005B2 (en) 4-azaindole derivatives
CN106255689B (en) Heteroaryl SYK Inhibitors
KR101986484B1 (en) Substituted quinolines and their use as medicaments
PE20090493A1 (en) DERIVATIVES OF 6-CYCLOAMINE-3- (PYRIDAZIN-4-IL) IMIDAZO [1,2-b] -PYRIDAZINE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
WO2018071606A1 (en) Compounds and methods for the targeted degradation of androgen receptor
MX2012005284A (en) Compounds and methods for kinase modulation, and indications therefor.
HRP20191937T1 (en) HEXAHYDROPYROLO [3,4-C] PYROL DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN INHIBITORS (ATX) AND AS LYSOPHOSPHATIC ACID (LPA) PRODUCTION INHIBITORS FOR THE TREATMENT OF EXAMPLE. KIDNEY DISEASES
HRP20192274T1 (en) NEW DERIVATIVES OF OCTAHYDRO-PYROL (3,4-C] -PYROL AND THEIR ANALYSES AS AUTOTAXIN INHIBITORS
JP2017510576A5 (en)
HRP20170484T1 (en) Novel fused pyridine compounds as casein kinase inhibitors
KR20150083833A (en) Heteroaromatic compounds as pi3 kinase modulators and methods of use
CN104602692A (en) Aminoquinolines as Kinase Inhibitors
AR084515A1 (en) NITROGEN HETEROCICLICAL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF DISEASES ASSOCIATED WITH THE CENTRAL NERVOUS SYSTEM SUCH AS PARKINSON AND ALZHEIMER, BETWEEN OTHER
PE20190204A1 (en) [8- (FENYLSULFONIL) -3,8-DIAZABICYCLO [3.2.1] OCT-3-IL] (1H-1,2,3-TRIAZOL-4-IL) METHANONES
CN116171280A (en) Casein kinase 1 delta modulator
JP2025521083A (en) Tetrahydropyrido[3,4-d]pyrimidine compounds as HPK1 inhibitors
HK40008526A (en) P2x7 modulators